Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
500
Market Cap
0.14M

Momentum Score

…

Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
-
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Isodiol International Inc develops, manufactures and distributes hemp-derived cannabinoid ingredients and consumer products for wellness and nutraceutical markets. Long-term growth may be supported by expanding global demand for regulated cannabinoid products, product innovation and the company's integrated manufacturing capabilities. Investors may find exposure to the evolving CBD/hemp sector and an upstream production footprint attractive.

Material risks include regulatory and legal uncertainty around cannabinoid products, limited liquidity and public reporting as an OTC Pink-listed small company, dependence on successful execution and external financing to scale, and strong competition.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
15.79M
Revenue Per Share
0.34
Gross Profit TTM
7.38M
Debt / Equity
-
ROE
-215.25%
Net Debt
7.69M
ROCE
-317.39%
Diluted EPS TTM
-0.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Type yearly yearly yearly yearly yearly
Date 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Income before tax -120.91M -35.73M -4.29M -6.71M -0.72M
Minority interest 0.00M 0.00M 0.00M - -
Net income -125.91M -36.02M -4.29M -6.71M -0.72M
Selling general administrative 36.92M 30.06M 3.44M 1.92M 0.72M
Gross profit 7.38M 8.88M 0.13M 0.01M 0.00M
Reconciled depreciation 2.06M 1.11M - - -
Ebit -38.48M -22.98M -3.06M -6.65M -0.72M
Ebitda -112.88M -34.62M - - -
Non operating income net other 0.00M 0.00M 0.00M - -
Operating income -31.72M -22.89M -3.45M -1.91M -0.72M
Other operating expenses 0.00M 0.00M 0.00M - -
Interest expense 5.97M 0.00M 0.00M 0.00M 0.00M
Tax provision -0.30M 0.29M - - -
Net interest income -5.97M -0.00M -0.07M - -
Extraordinary items 0.00M 0.00M 0.00M - -
Non recurring 0.00M 0.00M 0.00M - -
Other items 0.00M 0.00M 0.00M - -
Income tax expense -0.30M 0.29M 0.00M 0.00M 0.00M
Total revenue 22.25M 19.14M 0.36M 0.01M 0.00M
Total operating expenses 53.96M 42.03M 3.81M 0.00M 0.00M
Cost of revenue 14.87M 10.25M 0.23M 0.00M 0.00M
Total other income expense net -83.23M -12.84M -0.76M -4.74M -4.74M
Discontinued operations -5.30M -5.30M -5.30M - -
Net income from continuing ops -120.61M -36.02M -4.29M -6.71M -0.72M
Net income applicable to common shares -125.91M -36.02M -4.29M -6.71M -0.72M
Preferred stock and other adjustments 0.00M 0.00M 0.00M - -
Breakdown 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Type yearly yearly yearly yearly yearly
Date 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Total assets 23.62M 54.47M 2.28M 0.37M 0.06M
Intangible assets 0.00M 8.15M 0.00M - -
Other current assets 0.00M 0.00M 0.00M 0.03M 0.05M
Total liab 16.69M 6.70M 0.37M 0.95M 0.33M
Total stockholder equity 6.93M 47.77M 1.90M -0.57M -0.27M
Deferred long term liab 0.00M 0.29M 0.11M - -
Other current liab 3.05M 5.13M 0.00M - -
Common stock 176.98M 90.14M 14.34M 6.11M 0.45M
Capital stock 176.98M - - - -
Retained earnings -175.81M -49.90M -13.88M -7.41M -0.72M
Other liab 0.00M 0.00M 0.00M - -
Good will 0.00M 13.03M 0.00M - -
Other assets 2.16M 8.81M 0.11M - -
Cash 0.40M 15.55M 0.72M 0.08M 0.01M
Total current liabilities 11.50M 6.70M 0.38M 0.95M 0.33M
Net debt 7.69M - - - -
Short term debt 0.00M 0.00M 0.00M 0.72M 0.25M
Short long term debt 2.91M 0.00M 0.25M 0.72M 0.25M
Other stockholder equity 5.76M 7.52M 1.44M 0.73M 0.01M
Property plant equipment 1.62M 1.06M 0.06M - -
Total current assets 19.84M 22.84M 1.36M 0.37M 0.06M
Long term investments 0.00M 0.87M 0.86M - -
Net tangible assets 6.93M 26.88M 1.90M -0.57M -0.27M
Short term investments 2.47M 0.00M 0.62M - -
Net receivables 13.90M 4.97M 0.15M 0.05M 0.00M
Long term debt 5.19M 0.00M 0.00M - -
Inventory 0.86M 1.84M 0.43M 0.21M -
Accounts payable 5.48M 1.57M 0.13M 0.23M 0.08M
Total permanent equity 0.00M 0.00M 0.00M - -
Noncontrolling interest in consolidated entity 0.00M 0.00M 0.00M - -
Temporary equity redeemable noncontrolling interests 0.00M 0.00M 0.00M - -
Accumulated other comprehensive income 0.00M 0.00M 0.00M - -
Additional paid in capital 0.00M 0.00M 0.00M - -
Common stock total equity 0.00M 0.00M 0.00M - -
Preferred stock total equity 0.00M 0.00M 0.00M - -
Retained earnings total equity 0.00M 0.00M 0.00M - -
Treasury stock 0.00M 0.00M 0.00M - -
Accumulated amortization 0.00M 0.00M 0.00M - -
Non currrent assets other 3.78M -0.00M -0.00M - -
Deferred long term asset charges 0.00M 0.00M 0.00M - -
Non current assets total 3.78M 31.63M 0.92M - -
Capital lease obligations 0.00M 0.00M 0.00M - -
Long term debt total 0.00M 0.00M 0.00M - -
Breakdown 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Type yearly yearly yearly yearly yearly
Date 2019-03-31 2018-03-31 2017-03-31 2016-03-31 2015-03-31
Investments -2.54M -2.54M -2.54M -0.25M -0.25M
Change to liabilities 7.66M 0.20M 0.10M 0.26M 0.08M
Total cashflows from investing activities -16.48M -16.64M -0.39M -0.29M -0.29M
Net borrowings 7.90M 7.90M -0.35M 0.77M 0.25M
Total cash from financing activities 24.70M 55.09M 3.84M 1.25M 0.51M
Change to operating activities -1.78M -0.70M -0.07M 0.03M -0.05M
Net income -125.91M -36.02M -4.29M -6.71M -0.72M
Change in cash -15.15M 14.83M 0.61M 0.07M 0.01M
Begin period cash flow 15.55M 0.72M 0.11M - -
End period cash flow 0.40M 15.55M 0.72M 0.11M -
Total cash from operating activities -24.03M -23.48M -2.84M -1.18M -0.50M
Issuance of capital stock 15.80M - - - -
Depreciation 1.95M 0.98M 0.98M - -
Other cashflows from investing activities 1.33M 0.16M 0.16M - -
Dividends paid 0.00M 0.00M 0.00M - -
Change to inventory 0.98M -1.83M -0.15M -0.21M -0.21M
Change to account receivables -7.99M -2.98M -0.08M -0.03M -0.00M
Sale purchase of stock 0.00M 0.00M 3.66M 0.28M 0.26M
Other cashflows from financing activities -0.88M -1.57M -0.05M 0.20M 0.20M
Change to netincome 100.94M 16.75M 1.65M 5.48M 0.20M
Capital expenditures 0.93M 1.21M 0.39M 0.04M 0.04M
Change receivables 0.00M 0.00M 0.00M - -
Cash flows other operating 0.00M 0.00M 0.00M - -
Exchange rate changes 0.00M 0.00M 0.00M - -
Cash and cash equivalents changes 0.00M 0.00M 0.00M - -
Change in working capital -1.43M -5.01M - - -
Stock based compensation 0.48M - - - -
Other non cash items 18.99M 9.28M - - -
Free cash flow -28.51M -30.53M - - -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ISOLF
Isodiol International Inc
-
-%
0.00 - - 0.01 4.70 0.37 -0.06
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

Isodiol International Inc

Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.

200 Granville Street, Vancouver, BC, Canada, V6C 1S4

604 409 4409

Name Title Year Born
Mr. Marcos Agramont CEO & Director NA
Mr. Patrick Edward Ogle J.D., L.L.M. COO & Director NA
Mr. Marvin Washington VP & Director of Bus. Devel. and Director NA
Mr. Soheil Samimi Advisor NA
Mr. Andrew Stanton Alvis Pres, Interim CFO & Director NA
Mr. Kevin W. Swadish Chief Revenue Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…